Oral Norovirus Vaccine Candidate Successfully Tested in Human Challenge Trial
8 Articles
8 Articles
Oral norovirus vaccine candidate successfully tested in human challenge trial
Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against norovirus infection. Findings show a 30% reduction in infection rates among vaccinated participants compared to those receiving a placebo, along with reduced viral shedding and increased levels of protective antibodies in blood and mucosal tissues.
Oral Norovirus Vaccine Generates Immunity, Reduces Viral Shedding in Phase II
Often dubbed the “perfect pathogen,” norovirus is a highly contagious virus responsible for acute gastroenteritis (AGE) outbreaks worldwide. It spreads through contaminated food, water, person-to-person contact, and even aerosolized particles. For vulnerable populations like children and older adults, infections frequently require hospitalization and intravenous rehydration. Despite its significant public health impact, an effective vaccine has …
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage